Chlorzoxazone vs. Cyclobenzaprine: Muscle Relaxant Comparison for PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Chlorzoxazone (Parafon Forte, Lorzone) and cyclobenzaprine (Flexeril) are both centrally acting muscle relaxants, but chlorzoxazone acts primarily at the spinal cord level with a milder sedation profile. Understanding this distinction helps PI attorneys interpret pharmacy records where less common muscle relaxants appear.

Chlorzoxazone (Parafon Forte DSC, Lorzone) is a centrally acting muscle relaxant that works primarily at the spinal cord and subcortical brain levels, while cyclobenzaprine (Flexeril, Amrix) acts in the brainstem with significant sedative effects. In personal injury pharmacy records, chlorzoxazone is less commonly seen than cyclobenzaprine, and its presence signals a specific clinical rationale that attorneys should understand when building the demand package.

• Cyclobenzaprine is the most commonly prescribed muscle relaxant in PI cases, with significant sedation as its primary limitation
• Chlorzoxazone acts at the spinal cord level with generally milder sedation, making it an alternative when alertness preservation is important
• Both are FDA-approved for acute musculoskeletal conditions and neither is a controlled substance
• Chlorzoxazone requires hepatic function monitoring due to rare but serious hepatotoxicity risk
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that contextualizes muscle relaxant selection within the patient's full medication profile and clinical presentation

Mechanism of Action

Cyclobenzaprine acts centrally in the brainstem, reducing tonic somatic motor activity. It is structurally similar to tricyclic antidepressants and shares their sedative and anticholinergic side-effect profile. Cyclobenzaprine reduces muscle spasm through central depression of motor neuron activity rather than through any direct effect on skeletal muscle.

Chlorzoxazone also acts centrally but primarily at the spinal cord and subcortical levels of the brain. It inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm. By acting lower in the central nervous system hierarchy (spinal cord rather than brainstem), chlorzoxazone generally produces less cognitive sedation than cyclobenzaprine while still providing meaningful spasm relief.

Side-by-Side Comparison

Clinical Significance for Personal Injury

Cyclobenzaprine is the expected muscle relaxant in most PI pharmacy records. Its presence is clinically routine for acute post-traumatic muscle spasm, and attorneys encounter it frequently in whiplash, lumbar strain, and multi-site soft tissue injury cases.

Chlorzoxazone appearing in the pharmacy record is less common and signals a specific prescribing rationale. The most common clinical scenarios include: the patient requires muscle relaxation but cannot tolerate cyclobenzaprine's sedation (particularly if the patient needs to continue working, driving, or participating in physical therapy during treatment); the physician prefers a spinal-cord-level mechanism for spasm originating from spinal or paraspinal muscle groups; or the patient has contraindications to other muscle relaxants.

Attorneys should also note that chlorzoxazone causes a benign discoloration of urine to orange or reddish-purple. This side effect is harmless but can cause patient anxiety if not explained — its documentation in the medical record demonstrates that the physician provided appropriate patient counseling.

A pharmacy record showing cyclobenzaprine followed by chlorzoxazone documents that the treating physician needed to modify the muscle relaxant regimen. This transition most commonly reflects cyclobenzaprine intolerance due to excessive sedation — a clinically reasonable adjustment that documents ongoing spasm requiring treatment.

When Physicians Choose One Over the Other

Physicians select cyclobenzaprine when:

• Acute muscle spasm requires aggressive first-line treatment
• Sedation is not a concern or may be desirable (nighttime use, severe acute pain)
• The physician follows standard prescribing algorithms that default to cyclobenzaprine
• Short-term therapy (2-3 weeks) is the expected duration

Physicians select chlorzoxazone when:

• The patient needs muscle relaxation without significant cognitive impairment or daytime sedation
• Spasm originates primarily from spinal or paraspinal musculature where chlorzoxazone's spinal-cord-level mechanism may be more targeted
• The patient has intolerable anticholinergic side effects from cyclobenzaprine (dry mouth, urinary retention, constipation)
• The physician wants a muscle relaxant with a different side-effect profile to improve medication adherence

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Chlorzoxazone is the muscle relaxant we see when a physician is specifically managing sedation burden. In PI cases where the patient is trying to maintain employment or participate in daily physical therapy sessions, excessive drowsiness from cyclobenzaprine can actually impede recovery. Switching to chlorzoxazone documents that the physician is actively managing the patient's functional capacity."

Hepatotoxicity Monitoring

One important clinical distinction is chlorzoxazone's rare but serious hepatotoxicity risk. There have been post-marketing reports of severe hepatocellular injury, including fatal cases, associated with chlorzoxazone use. Physicians who prescribe chlorzoxazone should monitor liver function tests, and any signs of hepatotoxicity (jaundice, elevated LFTs, right upper quadrant pain) require immediate discontinuation. This monitoring requirement may appear in the medical records alongside the pharmacy lien and is evidence of appropriate clinical oversight.

For more on muscle relaxant prescribing in PI, see Muscle Relaxant Comparison for Injury Cases. For a comprehensive overview of cyclobenzaprine in PI, read Cyclobenzaprine After Rear-End Collision.